157 related articles for article (PubMed ID: 16118626)
1. Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders.
O'Malley DP; Kim YS; Perkins SL; Baldridge L; Juliar BE; Orazi A
Mod Pathol; 2005 Dec; 18(12):1550-61. PubMed ID: 16118626
[TBL] [Abstract][Full Text] [Related]
2. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
3. Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.
Prakash S; Hoffman R; Barouk S; Wang YL; Knowles DM; Orazi A
Mod Pathol; 2012 Jun; 25(6):815-27. PubMed ID: 22388763
[TBL] [Abstract][Full Text] [Related]
4. Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia.
O'Malley DP; Orazi A; Wang M; Cheng L
Mod Pathol; 2005 Dec; 18(12):1562-8. PubMed ID: 16118625
[TBL] [Abstract][Full Text] [Related]
5. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
[TBL] [Abstract][Full Text] [Related]
6. Benign extramedullary myeloid proliferations.
O'Malley DP
Mod Pathol; 2007 Apr; 20(4):405-15. PubMed ID: 17334344
[TBL] [Abstract][Full Text] [Related]
7. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
9. Extramedullary hematopoietic proliferations, extraosseous plasmacytomas, and ectopic splenic implants (splenosis).
Nappi O; Boscaino A; Wick MR
Semin Diagn Pathol; 2003 Nov; 20(4):338-56. PubMed ID: 14694984
[TBL] [Abstract][Full Text] [Related]
10. Fine-needle aspiration diagnosis of clonal extramedullary hematopoiesis in a case of myeloproliferative neoplasm.
Shponka V; Bone K; Nomani L; Hunt B
Diagn Cytopathol; 2022 Feb; 50(2):E43-E46. PubMed ID: 34617678
[TBL] [Abstract][Full Text] [Related]
11. Splenic hematopoiesis in polycythemia vera. A morphologic and immunohistologic study.
Wolf BC; Banks PM; Mann RB; Neiman RS
Am J Clin Pathol; 1988 Jan; 89(1):69-75. PubMed ID: 3276145
[TBL] [Abstract][Full Text] [Related]
12. A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological remission.
Hagiwara S; Yuo A; Miwa A; Takezako N; Hirano N; Togawa A
Int J Hematol; 1998 Jun; 67(4):411-6. PubMed ID: 9695415
[TBL] [Abstract][Full Text] [Related]
13. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
[TBL] [Abstract][Full Text] [Related]
14. The spleen microenvironment influences disease transformation in a mouse model of KIT
Pelusi N; Kosanke M; Riedt T; Rösseler C; Seré K; Li J; Gütgemann I; Zenke M; Janzen V; Schorle H
Sci Rep; 2017 Jan; 7():41427. PubMed ID: 28128288
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.
Stevens EC; Rosenthal NS
Am J Clin Pathol; 2001 Aug; 116(2):177-82. PubMed ID: 11488063
[TBL] [Abstract][Full Text] [Related]
17. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma.
O'Keane JC; Wolf BC; Neiman RS
Cancer; 1989 Apr; 63(8):1539-43. PubMed ID: 2924261
[TBL] [Abstract][Full Text] [Related]
18. Evidence for organ-specific stem cell microenvironments.
Ghinassi B; Martelli F; Verrucci M; D'Amore E; Migliaccio G; Vannucchi AM; Hoffman R; Migliaccio AR
J Cell Physiol; 2010 May; 223(2):460-70. PubMed ID: 20112287
[TBL] [Abstract][Full Text] [Related]
19. Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders.
Remstein ED; Kurtin PJ; Nascimento AG
Am J Surg Pathol; 2000 Jan; 24(1):51-5. PubMed ID: 10632487
[TBL] [Abstract][Full Text] [Related]
20. Myelopoiesis and myeloproliferative disorders.
Raskin RE
Vet Clin North Am Small Anim Pract; 1996 Sep; 26(5):1023-42. PubMed ID: 8863389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
